Dna X (SONM) Net Income towards Common Stockholders (2018 - 2025)
Historic Net Income towards Common Stockholders for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$4.8 million.
- Dna X's Net Income towards Common Stockholders fell 8921.18% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.0 million, marking a year-over-year decrease of 16253.66%. This contributed to the annual value of -$34.3 million for FY2024, which is 1033701.49% down from last year.
- According to the latest figures from Q3 2025, Dna X's Net Income towards Common Stockholders is -$4.8 million, which was down 8921.18% from -$7.5 million recorded in Q2 2025.
- In the past 5 years, Dna X's Net Income towards Common Stockholders registered a high of $527000.0 during Q3 2023, and its lowest value of -$22.3 million during Q4 2024.
- For the 5-year period, Dna X's Net Income towards Common Stockholders averaged around -$5.2 million, with its median value being -$4.2 million (2022).
- Per our database at Business Quant, Dna X's Net Income towards Common Stockholders surged by 13277.36% in 2023 and then tumbled by 229870.69% in 2024.
- Dna X's Net Income towards Common Stockholders (Quarter) stood at -$11.7 million in 2021, then surged by 89.91% to -$1.2 million in 2022, then rose by 21.69% to -$928000.0 in 2023, then plummeted by 2298.71% to -$22.3 million in 2024, then surged by 78.65% to -$4.8 million in 2025.
- Its Net Income towards Common Stockholders stands at -$4.8 million for Q3 2025, versus -$7.5 million for Q2 2025 and $458000.0 for Q1 2025.